CinRx is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success and accelerate promising new medicines to patients. By integrating our deep operational and clinical expertise with a thoughtful portfolio model, we establish the optimal development trajectory – a drug development superhighway.  Our experienced team of life science leaders ensures high-potential medicines are financially and operationally championed with the most efficient route from the bench to the patient.



Jon Isaacsohn
Founder and Chief Executive Officer

Dr. Jon Isaacsohn has served as Chief Executive Officer of CinRx Pharma since founding the company in 2015 and serves as a member of the company’s board of directors. During his career, Jon has been involved in developing hundreds of drugs from protocol design to global submission in various therapeutic areas, including cardio-metabolic, CNS, GI, oncology and infectious disease. Prior to founding CinRx Pharma in 2015, Jon served as Chief Medical Officer for Teva Pharmaceuticals where he was responsible for developing and overseeing the New Therapeutic Entities (NTEs) initiative across all therapeutic areas.  Jon also served as Executive Vice President, Head of Medical & Regulatory Affairs at Medpace, a global leader in research-based drug and device development for nearly 15 years.

He trained in Internal Medicine and Cardiology at Harvard Medical School and was a member of the cardiology faculty at Yale Medical School. Jon is also a co-founder of the Metabolic & Atherosclerosis Research Center in Cincinnati, US.

Brian Murphy

Brian Murphy, MD, MPH, FIDSA 
Chief Medical Officer 

Dr. Brian Murphy is board-certified in infectious disease, internal medicine, as well as pediatrics, and brings more than 20 years of leadership in clinical trial and drug development to the CinRx team as Chief Medical Officer.  

 He has most recently served as Senior Vice President of Medical Affairs and therapeutic lead for the Infectious Diseases franchise at Medpace.  Dr. Murphy has worked with large and small biopharmaceutical companies, government agencies, public-private partnerships, and academic centers during the approval of multiple products across various therapeutic areas. In his academic career at the University of Kentucky he led multi-disciplinary, translational, and clinical research projects sponsored by NIH (NIAID and NHLBI), CDC, Department of Defense, and pharma in a broad range of indications and patient populations at all phases of clinical development (pre-clinical through Phase IV).  

 Dr. Murphy received his Doctor of Medicine degree from the University of Louisville and his undergraduate diploma in biology from the University of Louisville. Dr Murphy also received his Master of Public Heath in Epidemiology from the University of Kentucky. Brian continues to uphold an academic appointment and maintains close ties with his clinical and research colleagues.

Mary Bond-31366WEB

Mary Bond, MS, MBA
Chief Translation Science Officer 

Mary Bond has been a critical part of CinRx since joining in 2018 and currently serves as the company’s Chief Translational Science Officer.  Mary is responsible for all discovery, non-clinical, and clinical pharmacology development activities including chemistry, manufacturing and controls (CMC), across the CinRx portfolio. 

Prior to joining CinRx Pharma, Mary’s experience includes roles of increasing responsibility within early development and clinical pharmacology at large pharmaceutical companies as well as a rapidly growing small to mid-size biopharmaceutical company. Mary brings a strong understanding of the financial, strategic, regulatory, and commercial considerations necessary for successful pharmaceutical product development of small and large molecules. 

Mary has a Master of Science in Microbiology from Thomas Jefferson University and a Master of Business Administration from Temple University. 



Jonathan Isaacsohn, MD, FACC

President and CEO, CinRx

August Troendle, MD

Chief Executive Officer, Medpace, Inc.

Jesse J. Geiger, CPA

President, Medpace, Inc.

Stephen P. Ewald, JD

General Counsel, Medpace, Inc.



5375 Medpace Way
Cincinnati, OH 45227